Sun Pharma arm gets relief from US court in patent infringement case

2018-12-27 09:29:38
Sun Pharma on Wednesday said its arm DUSA Pharmaceuticals has received relief from a US court in a patent infringement case.Massachusetts-based DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendant...

FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

2018-12-25 13:50:07
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adul...

FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

2018-12-25 13:43:32
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adul...

FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

2018-12-19 11:49:53
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity™ (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC)Motegrity, a selective...

FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

2018-12-19 11:49:29
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity™ (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC)Motegrity, a selective...

FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

2018-12-19 11:40:43
Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity™ (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC)Motegrity, a selective...

Drug Interactions

2018-12-05 10:16:06
Now You can check more then 40,000 Interactions between 2 or More drugs in Medico Market App & at www.medicomarket.in instantly, More interactions are being Uploaded... Stay tuned....Remain updated.

FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery

2018-12-04 15:00:39
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery

2018-12-04 14:55:29
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation Facebook Twitter Email to a friend Print this page

2018-12-03 12:46:14
The U.S. Food and Drug Administration approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. The FDA...